26 March 2018

The Sad Truth

One doesn't often see the pharma press actually be fully honest. Turns out that Merrimack Pharmaceuticals recently upped the sample size of a trial. The share dipped significantly; relative to 1Y high, nearly crashed. Here's an explanation:
The company plans to increase the number of participants to 100 from 80 citing rapid enrollment and "robust clinical interest." Frequently, however, a sponsor increases enrollment to improve the chances of a statistically valid result.

Ooo! Did baby bump his head on the floor?

No comments: